Experience

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million aggregate principal amount of its 2.00% senior convertible notes…

Davis Polk advised the joint book-running managers and representatives of the underwriters in an SEC-registered secondary offering of 18,000,000 shares of common stock of First BanCorp.,…

Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by L-3 Communications Corporation of $550 million of its 3.85% senior notes…

Davis Polk advised the joint book-running managers in connection with BPCE’s Section 3(a)(2) offering of $1.25 billion 2.750% notes due 2021 and $600 million 3.375% notes due 2026 under…

Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of €2.25 billion aggregate principal amount of senior notes, consisting of €1.25 billion floating…

Davis Polk is advising the buyer group consisting of Mr. Leilei Wang, Gongqingcheng Wujiang Xingyao Investment Management Partnership (Limited Partnership), Hexie Chengzhang Phase II (Yiwu)…

Davis Polk is advising JP Morgan as financial adviser to Teleflex Incorporated in connection with its approximately $1 billion acquisition of Vascular Solutions, Inc. The closing of the…

Davis Polk advised CSRA Inc. in connection with the November 30, 2016 amendment (the “First Amendment”) to its existing credit agreement dated as of November 27, 2015, with The Bank of…

Davis Polk advised Banco Santander Chile in connection with its Regulation S offering in Taiwan of $185 million aggregate principal amount of floating-rate notes due 2021.  Banco…

Davis Polk advised Banco Santander Chile in connection with its Regulation S offering in Switzerland of CHF125 million aggregate principal amount of 0.350% fixed-rate notes due 2025.  …